Aidi Pharmaceutical: The company's two innovative drugs in the field of anti-HIV have entered the National Medical Insurance Catalog
Aidi Pharmaceutical announced that the company's national Class 1 new drug in the field of anti-AIDS, enovirine tablets (trade name: Aibond), has passed the medical insurance negotiation and will continue to be included in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2023)" in the form of simple renewal;The company's other national Class 1 new drug in the field of anti-AIDS, enomitinib tablets (trade name: Fubond), has been included in the National Medical Insurance Catalogue (2023) for the first time through medical insurance negotiations.
Hongri Pharmaceutical: The product Xuebijing Injection continues to be included in the National Medical Insurance Catalog].
Hongri Pharmaceutical announced that the company's product Xuebijing Injection will continue to be included in the national medical insurance drug list. Xuebijing injection is a representative drug for severe pneumonia, sepsis and multiple organ dysfunction syndrome. In addition, the wrist oximeter of its wholly-owned subsidiary, VisionVision, has recently obtained the US FDA 510(K) certification, indicating that the product has the qualification to enter the U.S. market and is an important achievement of VisionSys in the field of blood oxygen monitoring.
Juhua Technology: Won the bid 35.8 billion yuan State Grid Procurement Project].
Juhua Technology announced that it received the notice of winning the bid issued by the State Grid of the State Grid Materials, and notified the company that it was the winning bidder of the "State Grid *** 89th batch of procurement in 2023 (the second electric energy meter (including electricity information collection) bidding and procurement of the marketing project)", with a total of 12 packages, with a total number of 1,020,700 and a total amount of 35.8 billion yuan.
Chipscreen Biosciences: The product chidamide tablets were renewed and entered the National Medical Insurance Catalog
Chipscreen Biosciences announced that the company's product chidamide tablets (Apsisa) were successfully negotiated and renewed and included in the national medical insurance catalog. Chidamide tablets are mainly used for the treatment of "patients with ** or refractory peripheral T-cell lymphoma (PTCL) who have received at least one prior systemic chemotherapy", and the medical insurance payment standard is 32242 yuan (5mg tablets), a decrease of 6% compared with the previous medical insurance payment standard, will further benefit the accessibility of patients.